z-logo
Premium
The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency
Author(s) -
Gehr Todd W B,
Rudy David W,
Matzke Gary R,
Kramer William G,
Sica Domenic A,
Brater D Craig
Publication year - 1994
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1994.98
Subject(s) - medicine , pharmacokinetics , furosemide , renal function , diuretic , bioavailability , crossover study , urology , oral administration , pharmacology , pathology , alternative medicine , placebo
Torsemide is a diuretic that acts in the thick ascending limb of the loop of Henle. Unlike furosemide, it undergoes substantial hepatic elimination and should not accumulate in patients with renal insufficiency. Therefore the pharmacokinetics of intravenous and oral torsemide and its metabolites were investigated in patients with chronic renal insufficiency. Two groups of 24 patients stratified by creatinine clearance (30 to 60 ml/min and <30 ml/min) were studied in two separate randomized dose escalating crossover studies, one using intravenous torsemide and the other using oral torsemide. The pharmacokinetics of both intravenous and oral torsemide were linear over the dosage range studied. Absolute bioavailability was essentially 100%. Renal clearance was greatly diminished and correlated with renal function. Total plasma clearance and half‐life were not related to renal function and were found to be similar to those of healthy subjects. The substantial nonrenal clearance of torsemide prevents accumulation in patients with chronic renal insufficiency. Clinical Pharmacology and Therapeutics (1994) 56, 31–38; doi: 10.1038/clpt.1994.98

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here